Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Anti-synthetase Syndrome Complicated by Pyogenic Myositis

Author(s): David Lizarazo, Karen Cifuentes , Paula Andrea Forero* and Hernan Páez

Volume 18, Issue 7, 2022

Published on: 01 March, 2022

Article ID: e221221199294 Pages: 4

DOI: 10.2174/1573405618666211222161022

Price: $65

Abstract

Background: Anti-synthetase syndrome is a rare autoimmune disorder characterized by autoantibodies against aminoacyl-tRNA-synthetases. Inflammatory myopathy and interstitial lung disease could be present among other manifestations. Anti-Jo-1 is the most common antisynthetase antibody and is the most likely to present with the classic triad (interstitial lung disease, myositis, and arthritis), and includes more muscle and joint involvement than patients with other antisynthetase antibodies.

Case Report: Here, we present a case of a 60-year-old female patient with a previous diagnosis of myositis, secondary to the anti-synthetase syndrome, a complication of pyogenic myositis.

Conclusion: The diagnosis of anti-synthetase syndrome is made by a multidisciplinary approach, and occasionally, muscle and/or lung biopsy is needed. Imaging studies, especially magnetic resonance imaging, based on findings such as muscle and fascial edema, and fatty tissue replacement, allow an optimal approach.

Keywords: Anti-synthetase syndrome, pyogenic myositis, musculoskeletal imaging, interstitial lung disease, arthritis, biopsy.

Graphical Abstract

[1]
Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum 2021; 51(1): 72-83.
[http://dx.doi.org/10.1016/j.semarthrit.2020.09.020] [PMID: 33360231]
[2]
Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 2020; 34(4): 101503.
[http://dx.doi.org/10.1016/j.berh.2020.101503] [PMID: 32284267]
[3]
Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77(282): 1019-38.
[http://dx.doi.org/10.1093/qjmed/77.1.1019] [PMID: 2267280]
[4]
Stenzel W, Preuße C, Allenbach Y, et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 2015; 84(13): 1346-54.
[http://dx.doi.org/10.1212/WNL.0000000000001422] [PMID: 25746564]
[5]
Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018; 75(12): 1528-37.
[http://dx.doi.org/10.1001/jamaneurol.2018.2598] [PMID: 30208379]
[6]
Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med 2016; 23(5): 218-26.
[http://dx.doi.org/10.1097/CPM.0000000000000171] [PMID: 27594777]
[7]
Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: Knowledge and uncertainties. Curr Opin Rheumatol 2018; 30(6): 664-73.
[http://dx.doi.org/10.1097/BOR.0000000000000555] [PMID: 30239350]
[8]
Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73(1): 227-32.
[http://dx.doi.org/10.1136/annrheumdis-2012-201800] [PMID: 23422076]
[9]
Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol 2017; 74(8): 992-9.
[http://dx.doi.org/10.1001/jamaneurol.2017.0934] [PMID: 28586844]
[10]
Andersson H, Kirkhus E, Garen T, Walle-Hansen R, Merckoll E, Molberg Ø. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: A cross-sectional study. Arthritis Res Ther 2017; 19(1): 17.
[http://dx.doi.org/10.1186/s13075-017-1219-y] [PMID: 28122635]
[11]
Curiel RV, Jones R, Brindle K. Magnetic resonance imaging of the idiopathic inflammatory myopathies: Structural and clinical aspects. Ann N Y Acad Sci 2009; 1154(1): 101-14.
[http://dx.doi.org/10.1111/j.1749-6632.2009.04386.x] [PMID: 19250233]
[12]
Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clin Exp Rheumatol 2019; 37(5): 858-61.
[PMID: 31074729]
[13]
Souza FH, Cruellas MG, Levy-Neto M, Shinjo SK. Síndrome antissintetase: Anti-PL-7, anti-PL-12 e anti-EJ. Rev Bras Reumatol 2013; 53(4): 352-7.
[http://dx.doi.org/10.1590/S0482-50042013000400007] [PMID: 24217667]
[14]
Marie I, Hatron P-Y, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013; 15(5): R149.
[http://dx.doi.org/10.1186/ar4332] [PMID: 24286268]

Rights & Permissions Print Cite
Article Metrics
22
1
© 2024 Bentham Science Publishers | Privacy Policy